Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., Smith, I. E. (2008) Platinum-based chemotherapy in triple-negative breast cancer. ANNALS OF ONCOLOGY, 19 (11). pp. 1847-1852. ISSN 0923-7534

Full text not available from this repository.

Abstract

Background: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. Patients and methods: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others. Results: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months). Conclusion: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.

Item Type:	Article
Authors (ICR Faculty only):	Smith, Ian and Johnston, Stephen
All Authors:	Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., Smith, I. E.
Uncontrolled Keywords:	breast cancer; early and advanced; platinum chemotherapy; triple-negative PHASE-II; INFUSIONAL CHEMOTHERAPY; MITOMYCIN-C; DNA-REPAIR; CISPLATIN; EPIRUBICIN; SUBTYPES; REGIMEN; TRIAL; FLUOROURACIL
Research teams:	Clinical Units > Breast Unit
Depositing User:	Users 10 not found.
Date Deposited:	24 Nov 2008 11:20
Last Modified:	13 Nov 2009 15:27
URI:	http://publications.icr.ac.uk/id/eprint/7209

Actions (login required)

View Item